Histologic confirmation of metastatic NSCLC. For Participants with known EGFR or ALK/ROS-1 mutations, prior therapy must have included an EGFR tyrosine kinase inhibitor or ALK/ROS-1 inhibitor, respectively. Participants may have had 1 prior line of anti-PD-1/PD-L1 therapy. Participants who received prior anti-PD-1/PD-L1 therapy must have progressed during or after treatment, but not prior to Week 12 of treatment.
Availability of archival (diagnostic) specimens or willing to undergo a pre-treatment biopsy.
Participants with treated brain metastases must have been treated with surgery and/or radiation therapy ≥ 21 days pre-study and must be clinically stable with no requirement for steroids.
Laboratory parameters for vital functions should be in the normal range.
Thank you for your interest in scheduling an appointment with our expert team. Please call us at 1-888-663-3488 and a patient services specialist can assist you with scheduling or click on one of the links below to fill out our convenient online form.